<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999231</url>
  </required_header>
  <id_info>
    <org_study_id>LTao-EC</org_study_id>
    <secondary_id>LTao</secondary_id>
    <nct_id>NCT01999231</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</brief_title>
  <official_title>Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Proswell Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the tests, small sample of clinical study about Recombinant Mycobacterium Tuberculosis
      Allergen ESAT6-CFP10 ( Recombination EC Allergen） healthy adults was carried out.

      24 healthy adults were included as study objects, they were randomly divided into four groups
      of different Recombinant Allergen EC dose (1, 5, 10μg/mL, maximum tolerated dose 20μg/mL, 6
      person/dose) for single arm intradermal injection.

      The main examination items :vital signs (breathing, heart rate, blood pressure, body
      temperature ) of each volunteer at 15min, 30min, 1h, 2h, 4h, 8h, 24h, 48h, 72h, 96h after
      injection, skin reactivity (redness and/or induration) diameter of injection sites,local
      reaction ( rash, pain, itching, and skin and mucous membranes ) ,a variety of adverse
      events,routine blood,routine urine, liver and kidney function, ECG and chest X-ray films
      before and 7 days after intradermal injection .

      Preliminary evaluation of safety and tolerability of Recombinant Allergen EC applied in
      humans, which can provide a safe dosage range for phase II clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study adopts an open, randomized study methods to carry out Recombinant EC
      Allergen on small sample of healthy adults.

      24 healthy adults were included as study objects, they were randomly divided into four groups
      of different Recombinant EC Allergen dose (1, 5, 10μg/mL, maximum tolerated dose 20μg/mL, 6
      person/dose) for single arm intradermal injection, and set up two people as replacement for
      each group (one male and one female).

      Intradermal injection into one third site of healthy subjects' left or right forearm palmaris
      with 0.1ml Recombinant EC Allergen for only one time.

      The main examination items :vital signs (breathing, heart rate, blood pressure, body
      temperature ) of each volunteer at 15min, 30min, 1h, 2h, 4h, 8h, 24h, 48h, 72h, 96h after
      injection, skin reactivity (redness and/or induration) diameter of injection sites,local
      reaction ( rash, pain, itching, and skin and mucous membranes ) ,a variety of adverse
      events,routine blood,routine urine, liver and kidney function, ECG and chest X-ray films
      before and 7 days after intradermal injection .

      In phaseⅠclinical study, each person can accept only one dose, After injection of the same
      dose of a volunteer group, be sure the next injection of a volunteer at 40 minutes interval.
      Different dose groups: the next dose test should be carried on in the case of no serious
      adverse events appear in 7days after the last one volunteer's injection in a former lower
      dose group.

      Statistical analysis is performed using SAS9.3 software, and all analytic process is
      routinization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Cases of Adverse Events With Participant Injection of ESAT6-CFP10</measure>
    <time_frame>within 7 days after the injections</time_frame>
    <description>The main examination items :vital signs (breathing, heart rate, blood pressure, body temperature ) of each volunteer at 15min, 30min, 1h, 2h, 4h, 8h, 24h, 48h, 72h, 96h after injection, skin reactivity (redness and/or induration) of injection sites,local reaction ( rash, pain, itching, and skin mucous membranes ) ,a variety of adverse events,routine blood,routine urine, liver and kidney function, ECG and chest X-ray films before and 7 days after intradermal injection .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Number of Participants Who Appear the Induration and/or Redness 2h After Application of ESAT6-CFP10</measure>
    <time_frame>within 2h after application of ESAT6-CFP10</time_frame>
    <description>We check the immune response( induration and/or redness) at 2h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Number of Participants Who Appear the Induration and/or Redness 24h After Application of ESAT6-CFP10</measure>
    <time_frame>24h after application of ESAT6-CFP10</time_frame>
    <description>We check the immune response( induration and/or redness) at 24h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Number of Participants Who Appear the Induration and/or Redness 48h After Application of ESAT6-CFP10</measure>
    <time_frame>48h after application of ESAT6-CFP10</time_frame>
    <description>We check the immune response( induration and/or redness) at 48h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Number of Participants Who Appear the Induration and/or Redness 72h After Application of ESAT6-CFP10</measure>
    <time_frame>72h after application of ESAT6-CFP10</time_frame>
    <description>We check the immune response( induration and/or redness) at 72h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Number of Participants Who Appear the Induration and/or Redness 96h After Application of ESAT6-CFP10</measure>
    <time_frame>96h after application of ESAT6-CFP10</time_frame>
    <description>We check the immune response( induration and/or redness) at 96h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1μg/ml ESAT6-CFP10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 1μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5μg/ml ESAT6-CFP10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 5μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10μg/ml ESAT6-CFP10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 10μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20μg/ml ESAT6-CFP10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 20μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ESAT6-CFP10</intervention_name>
    <description>32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .</description>
    <arm_group_label>1μg/ml ESAT6-CFP10</arm_group_label>
    <arm_group_label>5μg/ml ESAT6-CFP10</arm_group_label>
    <arm_group_label>10μg/ml ESAT6-CFP10</arm_group_label>
    <arm_group_label>20μg/ml ESAT6-CFP10</arm_group_label>
    <other_name>Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</other_name>
    <other_name>EC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged from 18 to 40 years old, age difference is not more than 10 years old within the
             same batch of healthy volunteers, the male to female ratio of cases is 1:1. Body mass
             index should be in the range of 20 to 27 Body Mass Index BMI: weight (Kg)/ height
             (M2);

          -  Agreed to participate in the test and sign the informed consent;

          -  Subjects should comply with the requirements of the clinical trial protocol and be
             followed;

          -  Subjects have no history of TB (Tuberculosis)or family history of tuberculosis;

          -  People have no pulmonary tuberculosis or extrapulmonary tuberculosis,respiratory
             symptom or systemic symptoms;

          -  People have no tuberculosis focus after examination by X-ray chest radiograph and
             sputum bacilli;

          -  Subjects have no acute or chronic disease, acute infectious diseases, dermatoses or
             skin allergy caused by various reasons;

          -  Physical condition: have no history of heart, liver, kidney, gastrointestinal tract,
             nervous system, or metabolic disturbance, etc. ECG, blood pressure, heart rate,
             respiratory status and lab test indexes including blood, urine, liver and kidney
             function, etc are all normal within 4 weeks before screening;

          -  No close contacts of tuberculosis;

          -  Subjects have not participated in other clinical drug trials or inoculated against
             other prophylactic and immune globulin in the nearly 3 months;

          -  Temperature is normal;

          -  Stop smoking, drinking and drinking contains caffeinated.

        Exclusion Criteria:

          -  Health people have close contacts of TB (Tuberculosis)patients, especially excreter in
             3 weeks before selection;

          -  Suffering from any other serious disease, e.g. during cancer treatment, autoimmune
             disease, progressive atherosclerosis, diabetes accompanied with complications, chronic
             obstructive pulmonary disease (COPD) needing oxygen therapy, acute or progressive
             liver or kidney disease, congestive heart failure, etc.;

          -  People have history of allergy, convulsions, epilepsy, cerebropathy, neurological
             symptoms and signs;

          -  Patients who have impaired or abnormal immune function, e.g. patients treated with
             immunosuppressor or immunopotentiator, received immunoglobulin preparation or blood
             products or plasma extraction outside the gastrointestinal tract in 3 months, human
             immunodeficiency virus or related diseases;

          -  Acute febrile illness and infection;

          -  Taking part in other clinic trials;

          -  Subjects have participated in any other clinical drug trials in 3 months before our
             clinical tests;

          -  Allergic constitution, e.g. patients have allergic history to two or more kinds of
             drugs or food, or drug components;

          -  Substance abuse and alcoholics ;

          -  Pregnant or breast feeding women;

          -  Mental or physical disability;

          -  Informed leavers;

          -  Any other cases that may influence the test evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuihua Lu, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Public Health Clinical Center</affiliation>
  </overall_official>
  <link>
    <url>https://wbca.cde.org.cn/wbca/clinmain.do?method=edit&amp;ckmIdCode=8BE5738082A97A9E5471F80B4F814FCF</url>
    <description>Center for drug evaluation, CFDA ,China</description>
  </link>
  <reference>
    <citation>van Pinxteren LA, Ravn P, Agger EM, Pollock J, Andersen P. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol. 2000 Mar;7(2):155-60.</citation>
    <PMID>10702486</PMID>
  </reference>
  <reference>
    <citation>Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, Kok-Jensen A, Andersen P, Weldingh K. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol. 2005 Apr;12(4):491-6.</citation>
    <PMID>15817755</PMID>
  </reference>
  <reference>
    <citation>Brusasca PN, Colangeli R, Lyashchenko KP, Zhao X, Vogelstein M, Spencer JS, McMurray DN, Gennaro ML. Immunological characterization of antigens encoded by the RD1 region of the Mycobacterium tuberculosis genome. Scand J Immunol. 2001 Nov;54(5):448-52.</citation>
    <PMID>11696195</PMID>
  </reference>
  <reference>
    <citation>Weldingh K, Andersen P. ESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs. PLoS One. 2008 Apr 23;3(4):e1978. doi: 10.1371/journal.pone.0001978.</citation>
    <PMID>18431468</PMID>
  </reference>
  <reference>
    <citation>Aagaard C, Govaerts M, Meikle V, Vallecillo AJ, Gutierrez-Pabello JA, Suarez-Güemes F, McNair J, Cataldi A, Espitia C, Andersen P, Pollock JM. Optimizing antigen cocktails for detection of Mycobacterium bovis in herds with different prevalences of bovine tuberculosis: ESAT6-CFP10 mixture shows optimal sensitivity and specificity. J Clin Microbiol. 2006 Dec;44(12):4326-35. Epub 2006 Sep 27.</citation>
    <PMID>17005738</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <results_first_submitted>January 7, 2015</results_first_submitted>
  <results_first_submitted_qc>March 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2015</results_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>ESAT6</keyword>
  <keyword>CFP10</keyword>
  <keyword>skin test</keyword>
  <keyword>diagnostic test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In September 4, 2013, the recruitment carried out in Shanghai Public Health Clinical Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1μg/ml ESAT6-CFP10</title>
          <description>We get 32 healthy subjects who all meet the standard of our protocol by comprehensive check-up and asked basic medical history .32 healthy subjects are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects who are injected drug , at the same time set up two people for substitute (one male and one female) .
Each participant intradermally inject only one dose of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 in one third site of left or right forearm palmaris .Within the same dose group two volunteer must be interval 40 minutes .
Make sure 1μg/ml ESAT6-CFP10 group finally finished injection and observed seven days with no serious adverse reaction, then carry out 5μg/ml ESAT6-CFP10 groups .</description>
        </group>
        <group group_id="P2">
          <title>5μg/ml ESAT6-CFP10</title>
          <description>We get 32 healthy subjects who all meet the standard of our protocol by comprehensive check-up and asked basic medical history .32 healthy subjects are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects who are injected drug , at the same time set up two people for substitute (one male and one female) .
Each participant intradermally inject only one dose of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 in one third site of left or right forearm palmaris .Within the same dose group two volunteer must be interval 40 minutes .
Make sure 5μg/ml ESAT6-CFP10 group finally finished injection and observed seven days with no serious adverse reaction, then carry out 10μg/ml ESAT6-CFP10 groups .</description>
        </group>
        <group group_id="P3">
          <title>10μg/ml ESAT6-CFP10</title>
          <description>We get 32 healthy subjects who all meet the standard of our protocol by comprehensive check-up and asked basic medical history .32 healthy subjects are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects who are injected drug , at the same time set up two people for substitute (one male and one female) .
Each participant intradermally inject only one dose of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 in one third site of left or right forearm palmaris .Within the same dose group two volunteer must be interval 40 minutes .
Make sure 10μg/ml ESAT6-CFP10 group finally finished injection and observed seven days with no serious adverse reaction, then carry out 20μg/ml ESAT6-CFP10 groups .</description>
        </group>
        <group group_id="P4">
          <title>20μg/ml ESAT6-CFP10</title>
          <description>We get 32 healthy subjects who all meet the standard of our protocol by comprehensive check-up and asked basic medical history .32 healthy subjects are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects who are injected drug , at the same time set up two people for substitute (one male and one female) .
Each participant intradermally inject only one dose of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 in one third site of left or right forearm palmaris .Within the same dose group two volunteer must be interval 40 minutes .</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Aged from 18 to 40 years old, the male to female ratio of cases is 1:1 in each group . Body mass index should be in the range of 20 to 27 .</population>
      <group_list>
        <group group_id="B1">
          <title>1μg/ml ESAT6-CFP10</title>
          <description>24 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、5μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、10μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、20μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10.Each dose group have six healthy subjects , at the same time set up two people for substitute (one male and one female) .</description>
        </group>
        <group group_id="B2">
          <title>5μg/ml ESAT6-CFP10</title>
          <description>24 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、5μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、10μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、20μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10.Each dose group have six healthy subjects , at the same time set up two people for substitute (one male and one female) .</description>
        </group>
        <group group_id="B3">
          <title>10μg/ml ESAT6-CFP10</title>
          <description>24 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、5μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、10μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、20μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10.Each dose group have six healthy subjects , at the same time set up two people for substitute (one male and one female) .</description>
        </group>
        <group group_id="B4">
          <title>20μg/ml ESAT6-CFP10</title>
          <description>24 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、5μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、10μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10、20μg/ml Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10.Each dose group have six healthy subjects , at the same time set up two people for substitute (one male and one female) .</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.00" spread="3.93"/>
                    <measurement group_id="B2" value="25.63" spread="4.13"/>
                    <measurement group_id="B3" value="30.07" spread="4.00"/>
                    <measurement group_id="B4" value="27.68" spread="3.79"/>
                    <measurement group_id="B5" value="27.10" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.32" spread="2.03"/>
                    <measurement group_id="B2" value="23.07" spread="2.05"/>
                    <measurement group_id="B3" value="22.05" spread="1.13"/>
                    <measurement group_id="B4" value="22.88" spread="2.11"/>
                    <measurement group_id="B5" value="22.58" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.17" spread="11.97"/>
                    <measurement group_id="B2" value="169.00" spread="9.67"/>
                    <measurement group_id="B3" value="163.00" spread="5.06"/>
                    <measurement group_id="B4" value="164.83" spread="11.11"/>
                    <measurement group_id="B5" value="166.50" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Cases of Adverse Events With Participant Injection of ESAT6-CFP10</title>
        <description>The main examination items :vital signs (breathing, heart rate, blood pressure, body temperature ) of each volunteer at 15min, 30min, 1h, 2h, 4h, 8h, 24h, 48h, 72h, 96h after injection, skin reactivity (redness and/or induration) of injection sites,local reaction ( rash, pain, itching, and skin mucous membranes ) ,a variety of adverse events,routine blood,routine urine, liver and kidney function, ECG and chest X-ray films before and 7 days after intradermal injection .</description>
        <time_frame>within 7 days after the injections</time_frame>
        <population>ESAT6-CFP10 allergen similar to TB-PPD(Tuberculin purified protein derivative ), main ingredients are protein and can cause specific skin allergy in the injection site ( such as redness, swelling, induration, blisters), besides other local reactions, is still listed as adverse events .</population>
        <group_list>
          <group group_id="O1">
            <title>1μg/ml ESAT6-CFP10</title>
            <description>Concentration of 1 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O2">
            <title>5μg/ml ESAT6-CFP10</title>
            <description>Concentration of 5 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O3">
            <title>10μg/ml ESAT6-CFP10</title>
            <description>Concentration of 10ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O4">
            <title>20μg/ml ESAT6-CFP10</title>
            <description>Concentration of 20 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; A single dose</description>
          </group>
        </group_list>
        <measure>
          <title>the Cases of Adverse Events With Participant Injection of ESAT6-CFP10</title>
          <description>The main examination items :vital signs (breathing, heart rate, blood pressure, body temperature ) of each volunteer at 15min, 30min, 1h, 2h, 4h, 8h, 24h, 48h, 72h, 96h after injection, skin reactivity (redness and/or induration) of injection sites,local reaction ( rash, pain, itching, and skin mucous membranes ) ,a variety of adverse events,routine blood,routine urine, liver and kidney function, ECG and chest X-ray films before and 7 days after intradermal injection .</description>
          <population>ESAT6-CFP10 allergen similar to TB-PPD(Tuberculin purified protein derivative ), main ingredients are protein and can cause specific skin allergy in the injection site ( such as redness, swelling, induration, blisters), besides other local reactions, is still listed as adverse events .</population>
          <units>cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Number of Participants Who Appear the Induration and/or Redness 2h After Application of ESAT6-CFP10</title>
        <description>We check the immune response( induration and/or redness) at 2h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
        <time_frame>within 2h after application of ESAT6-CFP10</time_frame>
        <population>Induration and/or redness is our main immune response of ESAT6-CFP10.</population>
        <group_list>
          <group group_id="O1">
            <title>1μg/ml ESAT6-CFP10</title>
            <description>Concentration of 1 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O2">
            <title>5μg/ml ESAT6-CFP10</title>
            <description>Concentration of 5 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O3">
            <title>10μg/ml ESAT6-CFP10</title>
            <description>Concentration of 10 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O4">
            <title>20μg/ml ESAT6-CFP10</title>
            <description>Concentration of 20 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>the Number of Participants Who Appear the Induration and/or Redness 2h After Application of ESAT6-CFP10</title>
          <description>We check the immune response( induration and/or redness) at 2h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
          <population>Induration and/or redness is our main immune response of ESAT6-CFP10.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Number of Participants Who Appear the Induration and/or Redness 24h After Application of ESAT6-CFP10</title>
        <description>We check the immune response( induration and/or redness) at 24h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
        <time_frame>24h after application of ESAT6-CFP10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1μg/ml ESAT6-CFP10</title>
            <description>Concentration of 1 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O2">
            <title>5μg/ml ESAT6-CFP10</title>
            <description>Concentration of 5 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O3">
            <title>10μg/ml ESAT6-CFP10</title>
            <description>Concentration of 10ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O4">
            <title>20μg/ml ESAT6-CFP10</title>
            <description>Concentration of 20 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; A single dose</description>
          </group>
        </group_list>
        <measure>
          <title>the Number of Participants Who Appear the Induration and/or Redness 24h After Application of ESAT6-CFP10</title>
          <description>We check the immune response( induration and/or redness) at 24h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Number of Participants Who Appear the Induration and/or Redness 48h After Application of ESAT6-CFP10</title>
        <description>We check the immune response( induration and/or redness) at 48h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
        <time_frame>48h after application of ESAT6-CFP10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1μg/ml ESAT6-CFP10</title>
            <description>Concentration of 1 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O2">
            <title>5μg/ml ESAT6-CFP10</title>
            <description>Concentration of 5 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O3">
            <title>10μg/ml ESAT6-CFP10</title>
            <description>Concentration of 10 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O4">
            <title>20μg/ml ESAT6-CFP10</title>
            <description>Concentration of 20 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>the Number of Participants Who Appear the Induration and/or Redness 48h After Application of ESAT6-CFP10</title>
          <description>We check the immune response( induration and/or redness) at 48h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Number of Participants Who Appear the Induration and/or Redness 72h After Application of ESAT6-CFP10</title>
        <description>We check the immune response( induration and/or redness) at 72h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
        <time_frame>72h after application of ESAT6-CFP10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1μg/ml ESAT6-CFP10</title>
            <description>Concentration of 1 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O2">
            <title>5μg/ml ESAT6-CFP10</title>
            <description>Concentration of 5 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O3">
            <title>10μg/ml ESAT6-CFP10</title>
            <description>Concentration of 10 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O4">
            <title>20μg/ml ESAT6-CFP10</title>
            <description>Concentration of 20 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>the Number of Participants Who Appear the Induration and/or Redness 72h After Application of ESAT6-CFP10</title>
          <description>We check the immune response( induration and/or redness) at 72h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Number of Participants Who Appear the Induration and/or Redness 96h After Application of ESAT6-CFP10</title>
        <description>We check the immune response( induration and/or redness) at 96h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
        <time_frame>96h after application of ESAT6-CFP10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1μg/ml ESAT6-CFP10</title>
            <description>Concentration of 1 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O2">
            <title>5μg/ml ESAT6-CFP10</title>
            <description>Concentration of 5 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O3">
            <title>10μg/ml ESAT6-CFP10</title>
            <description>Concentration of 10 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
          <group group_id="O4">
            <title>20μg/ml ESAT6-CFP10</title>
            <description>Concentration of 20 ug/ml;dosage form:Injection; 0.3 ml/bottle; Intradermal injection; 0.1 ml per participants; a single dose</description>
          </group>
        </group_list>
        <measure>
          <title>the Number of Participants Who Appear the Induration and/or Redness 96h After Application of ESAT6-CFP10</title>
          <description>We check the immune response( induration and/or redness) at 96h after application of ESAT6-CFP10 with vernier caliper. Using the standardized vernier caliper, measured transverse diameter and the longitudinal diameter of induration and/or redness in skin test parts if any participants appear induration and/or redness after application of ESAT6-CFP10.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>We collected and recorded all kinds of adverse event data within seven days after injection with ESAT6-CFP10.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1μg/ml ESAT6-CFP10</title>
          <description>Medicine Number 6 participant 24 h after test skin test, is observed local skin reactions and found subcutaneous hemorrhage ( 2 x 2 mm),48 h the subcutaneous hemorrhage is remain and becomes shallow ,72 h the subcutaneous hemorrhage is the same size and becomes lower shallow ,96 h the skin reaction has faded .This mild local skin reactions may be relevant with acupuncture of skin test , had nothing to do with experimental drugs by the judgement of principal investigator .
Medicine Number 12 participant occurred two cases of adverse events the seventh days after skin test :respectively pregnancy and a small amount of pleural effusion on both sides .This volunteer test results of a pregnancy test paper were negative in screening period,pregnancy test result were positive the seventh days after the skin test.</description>
        </group>
        <group group_id="E2">
          <title>5μg/ml ESAT6-CFP10</title>
          <description>Medicine Number 2 participant 15 min and 30 min after skin test is observed local skin reactions and all found that scattered red dot (32 x 25 mm )appeared .After 30min each time point local skin reactions were negative .
This mild local skin reactions may be relevant with alcohol allergy , had nothing to do with experimental drugs by the judgement of principal investigator .</description>
        </group>
        <group group_id="E3">
          <title>10μg/ml ESAT6-CFP10</title>
          <description>There is no adverse event.</description>
        </group>
        <group group_id="E4">
          <title>20μg/ml ESAT6-CFP10</title>
          <description>There is no adverse event.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>pregnancy</sub_title>
                <description>This volunteer test results of a pregnancy test paper were negative in screening period,pregnancy test result were positive the seventh days after the skin test.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>a small amount of effusion in bilateral chest</sub_title>
                <description>The participant had trace pleural effusion before injection.7 days after injection found a small amount of effusion was in bilateral chest .Participant refused follow-up and not have any discomfort ,so effusion had nothing to do with drugs .</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous Hemorrhage Caused by Injection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>alcohol allergy caused by disinfection of the injection site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>If the operator don't have standard measurement of transverse diameter and the vertical diameter of induration or redness ,we get unreliable data .The participant lost any follow-up will lead to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shuihua Lu</name_or_title>
      <organization>Shanghai Public Health Clinical Center</organization>
      <phone>(+86)18930811818</phone>
      <email>tubercle@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

